GlassScriptPhysician profile
Dorigen K Kasparek
NPI 1558329854
$1,730.12
in general payments reported to CMS, 2019-2025
30 companies · $123 in 2025
The $123 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $357 · 2020: $175 · 2021: $400 · 2022: $241 · 2023: $270 · 2024: $164 · 2025: $123.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $444 · Education: $113.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $444.39 |
| Education | $113.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $350.57 | 2019-2025 | |
| Astellas Pharma US INC | $196.76 | 2021-2025 | Veozah, Myrbetriq |
| Coopersurgical, INC. | $164.33 | 2019-2020 | |
| Organon LLC | $125.92 | 2021-2025 | Nexplanon |
| Mayne Pharma Commercial LLC | $80.22 | 2021-2023 | |
| Novo Nordisk INC | $65.70 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Therapeuticsmd, INC. | $65.26 | 2019-2020 | |
| Pfizer INC. | $60.67 | 2021-2022 | |
| Avion Pharmaceuticals | $49.82 | 2020-2023 | Balcoltra |
| Exeltis, USA INC. | $49.13 | 2020-2021 | |
| Agile Therapeutics, INC. | $43.98 | 2021 | |
| Scynexis, INC. | $41.87 | 2022 | |
| Sumitomo Pharma America, INC. | $40.36 | 2024-2025 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $37.16 | 2019-2021 | |
| Myovant Sciences INC. | $35.35 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Millicent US INC | $33.69 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Aspira Women'S Health INC | $32.90 | 2021-2024 | Ova1 |
| Amag Pharmaceuticals, INC. | $32.66 | 2019-2020 | |
| Vivus LLC | $32.12 | 2019-2021 | |
| Boston Scientific Corporation | $31.93 | 2019-2022 | |
| Baxter Healthcare | $23.65 | 2023 | Tisseel |
| Channel Medsystems, INC. | $22.10 | 2024 | |
| Exact Sciences Corporation | $18.69 | 2024 | Cologuard Collection Kit |
| Vertical Pharmaceuticals, LLC | $16.86 | 2019 | |
| Merck Sharp & Dohme LLC | $16.46 | 2020 | |
| Evofem Biosciences, INC. | $14.62 | 2020 | |
| Allergan, INC. | $13.39 | 2019 | |
| Lupin INC. | $13.21 | 2021 | |
| Roche Diagnostics Corporation | $11.80 | 2019 | |
| Meditrina | $8.94 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorigen Kasparek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.